WO2012154654A3 - Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9 - Google Patents

Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9 Download PDF

Info

Publication number
WO2012154654A3
WO2012154654A3 PCT/US2012/036749 US2012036749W WO2012154654A3 WO 2012154654 A3 WO2012154654 A3 WO 2012154654A3 US 2012036749 W US2012036749 W US 2012036749W WO 2012154654 A3 WO2012154654 A3 WO 2012154654A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
methods
imaging
dual
bone
Prior art date
Application number
PCT/US2012/036749
Other languages
English (en)
Other versions
WO2012154654A2 (fr
Inventor
Elizabeth A. Davis
Alan R. Davis
Eva M. Sevick-Muraca
Sunkuk KWON
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Priority to US14/115,990 priority Critical patent/US20140178293A1/en
Publication of WO2012154654A2 publication Critical patent/WO2012154654A2/fr
Publication of WO2012154654A3 publication Critical patent/WO2012154654A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, dans certains modes de réalisation, des procédés et des compositions permettant d'identifier la présence d'une ossification hétérotopique, ou le risque de développer une telle ossification, en particulier avant la minéralisation de l'os. Dans des modes de réalisation particuliers, des agents MMP-9 et/ou MMP-2 comprenant des parties d'imagerie double sont utilisés pour identifier des modèles de localisation de MMP-9 et/ou de MMP-2, respectivement, permettant ainsi de prédire une ossification hétérotopique.
PCT/US2012/036749 2011-05-06 2012-05-07 Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9 WO2012154654A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/115,990 US20140178293A1 (en) 2011-05-06 2012-05-07 Methods for imaging bone precursor cells using dual-labeled imaging agents to detect mmp-9 positive cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161483600P 2011-05-06 2011-05-06
US61/483,600 2011-05-06

Publications (2)

Publication Number Publication Date
WO2012154654A2 WO2012154654A2 (fr) 2012-11-15
WO2012154654A3 true WO2012154654A3 (fr) 2014-05-08

Family

ID=47139924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/036749 WO2012154654A2 (fr) 2011-05-06 2012-05-07 Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9

Country Status (2)

Country Link
US (1) US20140178293A1 (fr)
WO (1) WO2012154654A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150086482A1 (en) * 2007-01-11 2015-03-26 Immunomedics, Inc. Dye Conjugated Peptides for Fluorescent Imaging
US9283317B2 (en) * 2013-03-15 2016-03-15 General Electric Company Functional brown adipose tissue imaging technique
CN114984255B (zh) * 2022-05-31 2023-09-26 苏州大学 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093829A1 (en) * 2006-07-07 2010-04-15 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
US20100113327A1 (en) * 2006-11-17 2010-05-06 Van Leeuwen Johannes Petrus Theodor Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093829A1 (en) * 2006-07-07 2010-04-15 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
US20100113327A1 (en) * 2006-11-17 2010-05-06 Van Leeuwen Johannes Petrus Theodor Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AZHDARINIA ET AL.: "Characterization of chemical, radiochemical and optical properties of a dual -labeled MMP-9 targeting peptide.", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 19, no. ISS. 1, 6 May 2011 (2011-05-06), pages 3769 - 3776, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/21612930> [retrieved on 20120713] *
KANCZLER ET AL.: "Osteogenesis and angiogenesis: the potential for engineering bone.", EUROPEAN CELLS AND MATERIALS, vol. 15, 2 May 2008 (2008-05-02), pages 100 - 114, Retrieved from the Internet <URL:http://ww.ecmjournal.org/journal/papers/vo1015/pdf/v015a08.pdf> [retrieved on 20120713] *
WILGANOWSKI ET AL.: "Multi-modality imaging of bone formation by PET/CT and near-infrared imaging.", THE JOUMAL OF NUCLEAR MEDICINE, vol. 51, no. SUPPLE, 2010, pages 222, Retrieved from the Internet <URL:http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/51/2_MeetingAbstracts/222> [retrieved on 20120713] *

Also Published As

Publication number Publication date
US20140178293A1 (en) 2014-06-26
WO2012154654A2 (fr) 2012-11-15

Similar Documents

Publication Publication Date Title
AU2010253744A8 (en) Methods and apparatus for performing knee arthroplasty
WO2013063397A3 (fr) Dispositifs et procédés pour réaliser une arthroplastie de genou
EP3590474A3 (fr) Composant fémoral pour une prothèse du genou présentant des caractéristiques articulaires améliorées
AU2016216525A1 (en) Method and system for aligning a prosthesis during surgery
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
MX2012002705A (es) Derivados de xantina sustituidos.
EP2779928A4 (fr) Système de fixation centromédullaire pour la gestion de fractures pelviennes et acétabulaires
EP3848005A3 (fr) Élément porteur tibial pour prothèse du genou présentant des caractéristiques articulaires améliorées
WO2008154149A3 (fr) Traitement des tissus pour des implants non immunogènes
UA105911C2 (uk) Сульфонамідні похідні
GB2497475A (en) Kits, components and methods for tissue reconstruction
WO2009129260A3 (fr) Calycosine et ses analogues utilises dans le traitement des maladies induites par les recepteurs beta des oestrogenes
BR112015006916A2 (pt) cabeças femorais, inserções móveis, componentes acetabulares e junções modulares para implantes ortopédicos e métodos para uso de cabeças femorais, inserções móveis, componentes acetabulares e junções modulares para implantes ortopédicos
WO2009108383A3 (fr) Dérivés de xanthine substitués
GEP20135933B (en) Compounds as bradykinin b1 antagonists
WO2012154654A3 (fr) Procédés d&#39;imagerie de cellules osseuses précurseurs au moyen d&#39;agents d&#39;imagerie à double marquage, pour la détection de cellules positives mmp-9
WO2008156685A3 (fr) Cellules souches de tendons
ZA201303529B (en) Implantable device for preventive or curative treatment of fractures of the femur, associated ancillary device
MY185054A (en) Rolled collagen carrier
EP2640408A4 (fr) Compositions kératiniques pour le traitement d&#39;une déficience ou lésion osseuse
WO2012075422A3 (fr) Compositions et méthodes pour traiter les symptômes associés à des plaques amyloïdes
MX357774B (es) Derivado de benzodioxol y metodo de preparacion y uso del mismo.
MX2014012321A (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
WO2014203074A3 (fr) Utilisation de ghréline non acétylée, de ses fragments et ses analogues comme agents antioxydants
NZ595482A (en) Method of treating osteoporosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12782688

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14115990

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12782688

Country of ref document: EP

Kind code of ref document: A2